Published in Gastroenterology on April 24, 2015
Risk of recurrence of Barrett's esophagus after successful endoscopic therapy. Gastrointest Endosc (2016) 0.94
TissueCypher(™): A systems biology approach to anatomic pathology. J Pathol Inform (2015) 0.80
A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus. Cancer Epidemiol Biomarkers Prev (2016) 0.79
Advances in the management of Barrett's esophagus and early esophageal adenocarcinoma. Gastroenterol Rep (Oxf) (2015) 0.77
Esophageal Cancer Prevention. Gastroenterol Hepatol (N Y) (2016) 0.75
Etiology and Prevention of Esophageal Cancer. Gastrointest Tumors (2016) 0.75
Current Controversies in Radiofrequency Ablation Therapy for Barrett's Esophagus. Curr Treat Options Gastroenterol (2016) 0.75
Outcomes of Radiofrequency Ablation for Dysplastic Barrett's Esophagus: A Comprehensive Review. Gastroenterol Res Pract (2016) 0.75
Predictors of Progression in Barrett's Esophagus with Low-Grade Dysplasia: Results from a Multicenter Prospective BE Registry. Am J Gastroenterol (2017) 0.75
Disease Progression in Barrett's Low-Grade Dysplasia With Radiofrequency Ablation Compared With Surveillance: Systematic Review and Meta-Analysis. Am J Gastroenterol (2017) 0.75
Ablation Therapy for Barrett's Esophagus: New Rules for Changing Times. Curr Gastroenterol Rep (2017) 0.75
Current Management of Low-Grade Dysplasia in Barrett Esophagus. Gastroenterol Hepatol (N Y) (2017) 0.75
A trial of radiofrequency ablation for anal intraepithelial neoplasia. Int J Colorectal Dis (2016) 0.75
Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med (2009) 10.91
Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med (2011) 8.62
Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol (1983) 8.24
Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst (2008) 6.00
American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology (2011) 5.93
Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA (2014) 4.89
Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst (2011) 4.31
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut (2013) 4.29
Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol (2001) 4.16
Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology (2011) 3.44
Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol (2007) 3.00
Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology (2007) 2.86
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology (2007) 2.55
Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc (2014) 2.46
Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology (2001) 2.30
Efficacy and durability of radiofrequency ablation for Barrett's Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 2.28
Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology (2011) 2.27
Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut (2002) 2.16
Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut (2014) 2.07
Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol (2010) 1.90
Quantification of the placebo response in ulcerative colitis. Gastroenterology (1997) 1.86
The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol (2000) 1.84
Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol (2009) 1.76
Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology (2013) 1.57
Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies. Am J Gastroenterol (2008) 1.46
Comparative risk of recurrence of dysplasia and carcinoma after endoluminal eradication therapy of high-grade dysplasia versus intramucosal carcinoma in Barrett's esophagus. Gastrointest Endosc (2015) 1.45
Radiofrequency ablation for Barrett's esophagus with low-grade dysplasia: a hammer looking for a nail. Gastroenterology (2014) 1.40
Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol (2010) 1.35
Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol (2011) 1.32
Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort. Am J Gastroenterol (2005) 1.23
Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut (2012) 1.18
Low-grade dysplasia in Barrett's esophagus has a high risk of progression. Endoscopy (2007) 1.09
Esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia. Gastrointest Endosc (2015) 1.09
High-grade dysplasia in Barrett's esophagus: surveillance or operation? J Gastrointest Surg (2000) 0.97
How to manage a Barrett's esophagus patient with low-grade dysplasia. Clin Gastroenterol Hepatol (2008) 0.97
Predictive factors of coexisting cancer in Barrett's high-grade dysplasia. Surg Endosc (2006) 0.96
Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia. Clin Gastroenterol Hepatol (2014) 0.94
Esophageal cancer: associated factors with special reference to the Kashmir Valley. Tumori (2012) 0.90
Biomarkers for dysplastic Barrett's: ready for prime time? World J Surg (2015) 0.89
Aberrant TP53 detected by combining immunohistochemistry and DNA-FISH improves Barrett's esophagus progression prediction: a prospective follow-up study. Genes Chromosomes Cancer (2014) 0.88
Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis. Gut (2014) 0.84
Adherence to the 2011 American Gastroenterological Association medical position statement for the diagnosis and management of Barrett's esophagus. Dis Esophagus (2014) 0.78
Barrett's esophagus: who should receive ablation and how can we get the best results? Gastroenterology (2012) 0.76
Is rosiglitazone a promising treatment for ulcerative colitis? Nat Clin Pract Gastroenterol Hepatol (2008) 0.76
Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial. Gastroenterology (2015) 1.69
Oncogenic RAS regulates long non-coding RNA Orilnc1 in human cancer. Cancer Res (2017) 0.76